You are currently viewing Alpha Tau and MIM Software Are Collaborating On Alpha DaRT Treatment Planning

Jerusalem-based Alpha Tau Medical Ltd. (Nasdaq: DRTS) (“Alpha Tau“), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and MIM Software Inc. (“MIM Software”), a leading global provider of medical imaging software, have established collaboration between the two companies to provide treatment planning software for clinical sites using the Alpha DaRT therapy.

Under the terms of the agreement, the parties will collaborate on the use of MIM’s software suite, including MIM Symphony and MIMcloud®, for the development of new features and support for the Alpha DaRT across multiple potential indications, integration into all clinical trials involving the Alpha DaRT, and bundling the MIM software with the Alpha DaRT for future commercial sales in territories where the Alpha DaRT and MIM’s software are both approved.

The MIM Symphony treatment planning software guides clinicians through an easy step-by-step process to place Alpha DaRT sources precisely and create a patient-personalized treatment plan. MIM’s proprietary image manipulation capabilities, including MIM ReSlicer, and process and data management with MIM Workflows and MIMcloud, allow MIM Symphony to support treatment planning flexibly across multiple disease sites. Versatile guidance capabilities, including the ability to create custom 3D-printed access devices, assist in Alpha DaRT placement for challenging targets.

“We are thrilled to be taking this next step in our longstanding relationship with MIM,” noted Uzi Sofer, CEO of Alpha Tau. “While working with MIM for the past few years, we have seen this software’s ability to make treatment planning simpler and more powerful for the clinicians using the Alpha DaRT, and we are very excited to integrate our technologies and deliver the best therapeutic care for cancer patients. We continue to see increasing response rates in our clinical trials, culminating in the most recent data release from our U.S. pilot study treating cutaneous cancers, where we observed 100% complete response rates at 12 and 24 weeks after treatment. We believe that our improved treatment planning capabilities, including those developed with our most recent data release from our U.S. pilot study treating cutaneous cancers, where we observed 100% complete response rates at 12 and 24 weeks after treatment. ”

Alpha Tau Chief Operating Officer, Amnon Gat, added, “Our experience with the MIM team has been fantastic, and has instilled confidence that we can continue to develop together new treatment planning methods and workflows for our pipeline indications such as cancers of the brain, pancreas, and liver.”

“Our collaboration with Alpha Tau is an excellent opportunity for MIM to impact radiotherapy and patient outcomes,” said Andy Nelson, CEO of MIM Software. “We are very pleased with the response rates and are excited to be involved in providing an enhanced patient experience with Alpha DaRT.”

MIM Software Chief Scientific Officer, Jon Piper, added, “It’s been wonderful working together with Alpha Tau towards improving outcomes for patients whose options are limited today. We are hopeful that the planning, quality assurance, and standardization that MIM provides will allow clinicians to realize the potential of this transformational modality.”

About Alpha DaRT

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and dispersed while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor and to spare the healthy tissue around it.

About Alpha Tau Medical Ltd.

Founded in 2016, Alpha Tau Medical is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

About MIM Software Inc.

MIM Software is committed to enhancing patient care by providing customer-centered and innovative medical imaging and planning solutions in the fields of Radiation Oncology, Brachytherapy, Radiology, Nuclear Medicine, Urology, Neuroimaging, and Cardiac Imaging. The company’s products are used in over 5,000 centers worldwide.

MIM Software Inc. is a privately-held company headquartered in Cleveland, OH, with international offices in Beijing, Chengdu, and Brussels.

To learn more, visit mimsoftware.com..

Investor Relations Contact For Alpha Tau: IR AT alphatau.com

For MIM: bcarruthers AT mimsoftware.com

 

About JLM- BioCity

News on the many life science and healthcare companies in the Jerusalem area can be seen at https://jlm-biocity.org/jlm-biocity-innovations/

JLM-BioCity is a non-profit organization focused on developing and excelling Jerusalem’s bio-community.

We invite you, researcher, professional, investor, and executive to become part of our vision, in building Jerusalem’s Biomed eco-system.

If you want your company featured in our blogs, news releases, please contact: info at jlm-biocity.org